Caldoramide
Caldoramide is a pentapeptide isolated from the marine cyanobacterium Caldora penicillata. It has garnered attention due to its cytotoxic effects on cancer cells, making it a subject of interest in the field of cancer research[1]. This compound is part of a broader category of marine natural product peptides that have been identified for their therapeutic potential, including anti-proliferative activity against cells with oncogenic KRAS or HIF transcription factors[4][6].
The structure of caldoramide has been compared to other known peptides such as belamide A, dolastatin 10, and dolastatin 15, indicating a potential for significant bioactivity[12][19]. Its isolation alongside dolastatin 10, a highly potent anticancer compound, further underscores the importance of marine cyanobacteria as a source of novel bioactive compounds[15].
Research has focused on synthesizing the proposed structure of caldoramide to explore its anticancer activity further[10][15]. This effort is part of a larger trend towards leveraging natural products from marine cyanobacteria for developing new therapeutic agents, especially given the adverse side effects associated with many conventional cancer treatments[11]. Caldoramide's specific activity against various cancer cell lines, including human colon adenocarcinoma (HT-29), human colon carcinoma (HCT116), and human breast adenocarcinoma (MCF-7), has been documented, highlighting its potential as a candidate for further drug development[11].
In summary, caldoramide represents a promising area of research within the realm of marine-derived natural products with potential applications in cancer therapy. Its cytotoxic activity against cancer cells, coupled with ongoing efforts to understand and synthesize its structure, positions it as a compound of interest for future drug development initiatives.
Citations:
[1] https://en.wikipedia.org/wiki/Caldoramide
[2] https://www.researchgate.net/publication/304910259_Caldoramide_a_Modified_Pentapeptide_from_the_Marine_Cyanobacterium_Caldora_penicillata
[3] https://www.mayoclinic.org/drugs-supplements/pamidronate-intravenous-route/side-effects/drg-20067693
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918664/
[5] https://pubs.acs.org/doi/10.1021/acs.jnatprod.6b00203
[6] https://www.mdpi.com/1660-3397/15/11/354
[7] https://www.sciencedirect.com/science/article/pii/S0753332219309072
[8] https://www.mdpi.com/2075-1729/13/6/1411
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215049/
[10] https://www.researchgate.net/publication/324276488_Synthesis_and_anticancer_activity_of_the_proposed_structure_of_caldoramide_an_N_-peptidyltetramate_from_the_cyanobacterium_Caldora_penicillata
[11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301180/
[12] https://pubmed.ncbi.nlm.nih.gov/27380142/
[13] https://pubs.acs.org/doi/abs/10.1021/np500931q
[14] https://medlineplus.gov/druginfo/meds/a601163.html
[15] https://www.sciencedirect.com/science/article/abs/pii/S0040402018303727
[16] https://en.wikipedia.org/wiki/Laucysteinamide_A
[17] https://www.sciencedirect.com/science/article/abs/pii/B9780323992831000070
[18] https://research.si.edu/publication-details/?id=140388
[19] https://profiles.si.edu/display/sro_140388
[20] https://www.sciencedirect.com/science/article/pii/S0040402018303727